Partnership Between Volition and Fujifilm Vet Systems
VolitionRx Limited (NASDAQ: VNRX), a leading multi-national epigenetics company, has recently forged an agreement with Fujifilm Vet Systems Co. Ltd to revolutionize canine cancer detection. The collaboration focuses on enhancing their Nu.Q® Vet Cancer Test, with plans to introduce a chemiluminescent immunoassay (ChLIA) version for faster and more efficient testing.
Transforming Cancer Detection for Dogs
The initial agreement allowed Fujifilm Vet Systems to distribute the Nu.Q Vet Cancer Test using the manual ELISA format in veterinary practices. With the new automated platform being introduced via the Immunodiagnostic Systems (IDS) i10® analyzer, this collaboration will optimize the testing process significantly. Veterinary professionals in Japan are expected to see the benefits by summer 2025.
A Noteworthy Growth Opportunity
Dr. Jasmine Kway, the CEO of Volition, emphasized that the landscape for veterinary diagnostics in Japan is evolving. With an estimated seven million pet dogs in the country, this partnership offers a substantial opportunity for revenue generation. By incorporating an automated system, the efficiency in testing can meet the rising demand from veterinarians and pet owners alike.
Importance of Early Detection
Dr. Kway noted the critical need for early cancer detection, as cancer is the leading cause of death in adult dogs. The Nu.Q® Vet Cancer Test serves as a user-friendly and affordable solution that veterinary practices can utilize during regular check-ups. The enhancement to an automated platform means that earlier identification of health issues could significantly improve patients' outcomes.
Excitement in Veterinary Community
Kiyotaka Fujiwara, COO at Fujifilm Vet Systems, shared the enthusiasm around the continued success of the Nu.Q® Vet Cancer Test. Since its launch, over 1,000 veterinary hospitals in Japan have expressed interest in utilizing this test, underscoring the pivotal role it will play in canine healthcare. The automated system is expected to allow for a more rapid turnaround, addressing the pressing needs of the market.
Understanding the Nu.Q® Vet Cancer Test
The Nu.Q® Vet Cancer Test is designed primarily for older dogs, particularly those seven years and older, along with younger breeds that are deemed high-risk. With its affordability—averaging just $11 per test for central lab testing—it represents a cost-effective approach to ensuring the health of pets across various demographics.
FujiFilm Vet Systems: A Trusted Partner
FujiFilm Vet Systems is a highly established entity within the veterinary diagnostic market, possessing a broad network and relationships with approximately 11,000 veterinary facilities in Japan. Their commitment to providing reliable testing services through centralized laboratories enhances their capability to address complex examinations that may not be feasible in regular veterinary practices.
Volition's Commitment to Innovation
Volition remains steadfast in its mission to advance the science of epigenetics. Their extensive research focuses on developing blood tests that aid in the diagnosis and monitoring of various diseases, including cancers. The company is dedicated to crafting solutions that not only enhance diagnostic accuracy but also empower both veterinarians and pet owners.
The Future of Veterinary Diagnostics
This collaboration between Volition and Fujifilm Vet Systems marks an exciting chapter in the veterinary field. As they prepare to implement this innovative automation, they pave the way for increased efficiency, rapid results, and most importantly, better health outcomes for dogs. This partnership exemplifies how technology can transform traditional veterinary practices into modern, effective healthcare solutions.
Frequently Asked Questions
What is the Nu.Q® Vet Cancer Test?
The Nu.Q® Vet Cancer Test is a blood test designed for early detection of cancer in dogs, particularly benefiting older canines during routine check-ups.
How will the automation help veterinarians?
The automation will allow veterinarians to achieve faster test results, improving the overall efficiency of testing in veterinary practices.
What opportunities does this partnership create?
This collaboration offers new revenue opportunities for both Volition and Fujifilm Vet Systems, significantly impacting the veterinary diagnostics market.
Where will the test be available?
The Nu.Q® Vet Cancer Test will be available across a network of veterinary practices in Japan, with plans to expand its reach as automation is implemented.
Why is early detection important for dogs?
Early detection of cancer in dogs can lead to improved treatment outcomes and increase the chances of survival, making tools like the Nu.Q® Vet Cancer Test essential.
